



D. BORAL
— CAPITAL —



August 2025



\$120,000,000

Underwritten Public Offering
Co-Manager



*For more information
please contact:*

Investment Banking

David Lee
Senior Managing Director
Direct: +1 (929) 625 0988
dlee@dboralcapital.com

John Park
Vice President
Direct: +1 (929) 528-0864
jpark@dboralcapital.com

Patrick Lin
Analyst
Direct: +1 (929) 615-2558
plin@dboralcapital.com

Alex Piechucki
Analyst
Direct: +1 (929) 528-0907
apiechucki@dboralcapital.com

Equity Capital Markets

Philip Wiederlight
Chief Operating Officer
Direct: +1 (929) 625-1539
pwiederlight@dboralcapital.com

Mark Iorio
Director, Equity Capital Markets
Direct: +1 (929) 528-0913
miorio@dboralcapital.com

D. Boral Capital Acted as Co-Manager to Compass Therapeutics, Inc. (Nasdaq: CMPX) in Connection with its \$120,000,000 Underwritten Public Offering

Transaction Information

On August 12, 2025, Compass Therapeutics, Inc. ("Compass") (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of \$3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of \$2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the \$0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the Offering to Compass are expected to be approximately \$120,000,000, before deducting underwriting discounts and commissions and other offering expenses. The Offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

Compass intends to use the net proceeds from the Offering to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general corporate purposes.

D. Boral Capital LLC acted as Co-Manager for the Offering.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

About D. Boral Capital

D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.

A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately \$30 billion in capital since its inception in 2020, executing ~350 transactions across a broad range of investment banking products.

D. Boral Capital is a member of FINRA and SIPC.



D. BORAL
— CAPITAL —